Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage

Ying Xiong1, Wei Liu2, Qian Huang1, Jierong Wang1, Yanjun Wang1, Huijuan Li3 & Xuedong Fu1

Retinoblastoma is the most common intraocular malignancy in children with poor prognosis. The progression of retinoblastoma is dependent on a robust angiogenic response. Targeting both retinoblastoma cells and angiogenesis may therefore provide an alternative therapeutic strategy in retinoblastoma. Here, we demonstrated the inhibitory effects of tigecycline, a FDA-approved antibiotic, in retinoblastoma and angiogenesis in vitro and in vivo. We showed that tigecycline significantly inhibited growth and induced caspase-dependent apoptosis of multiple retinoblastoma cell lines. Tigecycline also effectively inhibited angiogenesis through suppressing capillary network formation, migration, proliferation and survival of human retinal microvascular endothelial cell (HREC). Mechanistically, tigecycline acts on both retinoblastoma cells and HREC via inhibiting mitochondrial protein translation, resulting in mitochondrial dysfunction, energy crisis, and oxidative damage. Importantly, we demonstrated the in vivo efficacy of tigecycline in inhibiting retinoblastoma and angiogenesis, and inducing oxidative stress on xenograft mouse model. In addition, ATP levels and growth rates were largely affected in retinoblastoma p0 cells that lacked mitochondrial respiration. Our work provides systematic pre-clinical evidence for repurposing tigecycline from its traditional use for retinoblastoma treatment. Our work demonstrates the essential roles of mitochondrial metabolism in both retinoblastoma and its angiogenesis.

Retinoblastoma is the most common childhood primary intraocular cancer, which occurs in 1/15,000 live births worldwide1. The clinical management of retinoblastoma is challenging and its prognosis is poor, particularly in developing countries2-5. Retinoblastoma is a heterogeneous disease with aberrant activation of oncogenes and suppression of the tumour suppressor genes, such as retinoblastoma 14. Retinoblastoma is initiated by the mutation of the tumor suppressor gene retinoblastoma 1 (RB1) and characterized by molecular heterogeneity and extensive vascularization5,6. Angiogenesis, the growth of new blood vessels from pre-existing ones, is tremendously important to retinoblastoma growth, survival and metastasis7. Therefore, the ideal therapeutic strategies for retinoblastoma are to target both tumor cells and angiogenesis.

Tigecycline is a broad spectrum antibiotic that acts on bacteria through binding to ribosome and suppressing protein synthesis8,9. It is clinically used to treat complicated skin and intra-abdominal infections, and community-acquired bacterial pneumonia10. Interestingly, substantial evidence on pre-clinical models demonstrate that tigecycline is a novel type of anti-cancer drug. At clinically achievable doses, tigecycline effectively kills leukaemias, renal and liver cancer cells, and significantly augments chemotherapy agents in vitro and in vivo11-13. Importantly, tigecycline exhibits preferentially anti-cancer activities with minimal toxicity in normal counterparts14,15. The mechanisms of tigecycline in cancer cells include inhibition of mitochondrial translation and Wnt/β-catenin, and autophagy activation14,15.

In this work, we are the first to investigate the effects of tigecycline on retinoblastoma and angiogenesis. We further analysed the underlying mechanism of tigecycline and validated the results obtained from in vitro cell culture system on retinoblastoma xenograft mouse model. Our work show that tigecycline is effective in inhibiting...
Results

Tigecycline effectively targets both retinoblastoma cells and angiogenesis. It is well known that angiogenesis plays essential roles in retinoblastoma progression and metastasis. To determine the possible effects of tigecycline in retinoblastoma, we investigated not only the growth and survival of retinoblastoma cells but also angiogenesis after tigecycline treatment. Three cell lines Y79, RB116 and WERI-Rb1 that represent in vitro human retinoblastoma models are used in our study. Of note, these cells express stem cell markers (e.g., Nanog and Oct3/4) and retinal progenitor markers (e.g., PAX6 and CHX10). In addition, Y79 and WER-Rb-1 contain RB1 mutations.

We found that tigecycline at 5 to 20 µM significantly inhibited proliferation in all tested retinoblastoma cell lines (Fig. 1A). Tigecycline also significantly increased Annexin V percentage in retinoblastoma cells in a dose- and time-dependent manner (Fig. 1B, C), suggesting that tigecycline induced apoptosis. In addition, tigecycline induced apoptosis starting from 24 hour (Fig. 1C). A pan-caspase inhibitor Z-VAD-fmk completely abolished the effects of tigecycline in inducing apoptosis (Fig. 1D), demonstrating that tigecycline induced apoptosis through activating caspase pathways.

We further demonstrated that tigecycline at 10 and 20 µM significantly inhibited proliferation and induced apoptosis in normal retinal epithelial cells, but to a lesser extent than in retinoblastoma cells (Supplementary Fig. S1). In addition, tigecycline at 5 µM significantly targeted retinoblastoma cells but did not affect normal retinal epithelial cells (Supplementary Fig. S1). Although differences in tigecycline's efficacy on normal and tumor cells was moderate, these results demonstrated that tigecycline had preferential activity on tumor cells. This is also consistent with other work and our previous findings on the selectivity of tigecycline on tumor than normal counterparts.

We performed in vitro angiogenesis assay by plating human retinal microvascular endothelial cells (HREC) onto Matrigel gel. We observed a rapid alignment and tubular structures formation within 6 hours in control. In contrast, HREC failed to form proper capillary structures in the presence of 5 and 10 µM tigecycline. Notably, hardly any tubular network formed in the presence of 20 µM tigecycline (Fig. 2A). We further found that tigecycline significantly inhibited HREC migration and proliferation, and induced apoptosis in a dose-dependent manner (Fig. 2B–D). Time course analysis of apoptosis indicated that tigecycline at 20 µM significantly induced apoptosis of endothelial cells starting from 36 hours drug treatment (Supplementary Fig. S2). Taken together, our results demonstrate that tigecycline targets multiple aspects of biological functions of both retinoblastoma cells and HREC.
Tigecycline inhibits mitochondrial protein translation, and induces mitochondrial dysfunctions and oxidative stress in retinoblastoma cell and HREC. Tigecycline acts as a protein synthesis inhibitor in bacteria. In addition, tigecycline has been demonstrated to have potent inhibitory activity on mitochondrial protein translation in human leukaemia and renal carcinoma cells. To determine whether the inhibitory effects of tigecycline on retinoblastoma cell and HREC is mediated by a similar mechanism, we investigated the mitochondrial translation via examining protein and mRNA levels of cytochrome c oxidase-1, 2 and 4 (Cox-1, Cox-2 and Cox-4, respectively). Although all three proteins are subunits of mitochondrial respiratory complex IV, Cox-1 and Cox-2 are mitochondrial DNA and only translated by mitochondrial ribosomes whereas Cox-4 is translated by nuclear ribosomes. We observed significantly decreased protein levels and increased mRNA levels of Cox-1 and 2 in Y79 cells and HREC exposed to tigecycline (Fig. 3A,B, and Supplementary Fig. S3). In contrast, tigecycline did not affect the mRNA or protein levels of Cox-4 (Fig. 3A,B). These results clearly show that tigecycline specifically inhibits mitochondrial protein translation in retinoblastoma cells and HREC.

Mitochondrial respiratory complexes I and IV but not II contain mitochondrially encoded protein subunits. Consistent with mitochondrial translation inhibition, tigecycline significantly inhibited activities of respiratory complexes I and IV but not II (Fig. 3C). Since mitochondrial respiration rely on the proper function of mitochondrial respiratory chains, we next analyzed the oxygen consumption rate (OCR, indicative of mitochondrial respiration). We observed the dose-dependent reduction on basal and maximal OCR levels in Y79 and HREC exposed to tigecycline (Fig. 3A,B, and Supplementary Fig. S3). In contrast, tigecycline did not affect the mRNA or protein levels of Cox-4 (Fig. 3A,B). These results clearly show that tigecycline specifically inhibits mitochondrial protein translation in retinoblastoma cells and HREC.

Tigecycline is ineffective in targeting mitochondrial respiration-deficient retinoblastoma \( \rho_0 \) cells. To further confirm that tigecycline targets a mitochondrial genome-encoded component of oxidative phosphorylation in retinoblastoma, we generated Y79 \( \rho_0 \) cells that lack mitochondrial DNA and are incapable of performing mitochondrial respiration. We successfully established Y79 \( \rho_0 \) cells from Y79 cells with the very minimal levels of mitochondrial DNA (eg, MT-CO2 and MT-ND6) without affecting nuclear DNA (eg, SDHA) (Fig. 6A). These \( \rho_0 \) cells also exhibit a remarkably reduced baseline OCR and reserved respiratory capacity compared to parental cells (Fig. 6B,C). In addition, these \( \rho_0 \) cells show significantly decreased ATP level and increase Las signaling.
inadequate growth (Fig. 6D,E). Notably, Y79 ρ0 cells are resistant to tigecycline in inducing apoptosis (Fig. 6F). Thus, our data indicate that tigecycline specifically targets a mitochondrial genome-encoded component of mitochondrial respiration in retinoblastoma.

**Figure 3.** Tigecycline inhibits mitochondrial translation in retinoblastoma and HREC. Tigecycline decreases protein level (A) and increases mRNA level (B) of Cox-1 and -2 without affecting protein and mRNA levels of Cox-4 in retinoblastoma cells and HREC. Transcript levels of each gene was normalized with β-actin. (C) Tigecycline suppresses mitochondrial respiratory complex I and IV but not II activity in Y79 and HREC cells. *p < 0.05, compared to control.

**Figure 4.** Tigecycline inhibits mitochondrial respiration and ATP production, and induces oxidative stress in retinoblastoma and HREC. Tigecycline significantly decreases basal (A) and maximal (B) OCR in a dose-dependent manner in Y79 and HREC. Tigecycline significantly decreases ATP (C) and increases mitochondrial superoxide (D) level in Y79 and HREC. *p < 0.05, compared to control.
Tigecycline inhibits retinoblastoma growth and angiogenesis, and induces oxidative stress in vivo. To investigate whether the data obtained from in vitro cell culture system are reproducible in in vivo, we investigated the effects of tigecycline on retinoblastoma growth and retinoblastoma angiogenesis in xeno-graft mouse model. We also analysed the oxidative stress level in retinoblastoma tumours. We found that tigecycline at 60 mg/kg significantly inhibited retinoblastoma growth in mice throughout the whole duration without affecting the mice body weight (Fig. 7 and Supplementary Table S1), indicating that tigecycline at tolerable dose has anti-retinoblastoma activity in mice. Immunohistochemistry staining of tigecycline-treated tumour tissue sections with anti-CD31 antibody (which stains tumour ECs) revealed a decreased tumour vascularization compared with control (Fig. 8A, indicated by white arrows). The average tumour vascular density of each tumour group, which included all lumen and non-lumen CD31 structures or cells, was significantly decreased tigecycline treatment (Fig. 8B). Of note, a significantly increased staining of oxidative stress markers HEL, and 4-HNE tigecycline-treated tumour tissue sections were observed (Fig. 8A,C,D). These results were in concordance with our in vitro data, and confirmed the inhibitory effects of tigecycline in retinoblastoma and angiogenesis and its ability in inducing oxidative stress.

Discussion
The majority of solid tumors, such as retinoblastoma, are largely dependent on angiogenesis to grow and spread. Histopathologically, retinoblastoma tumor shows perivascular sleeves consisting of neoplastic cells, demonstrating a close association of tumor cells with blood vessels24. High vascularization in retinoblastoma has been shown to be linked with chemoresistance, dissemination and poor prognosis16,25. In contrast, angiogenesis inhibition alone by bevacizumab or pigment epithelium-derived factor suppresses retinoblastoma growth without producing significant systemic toxicity16. Therefore, targeting angiogenesis as well as tumour cells as an alternative therapeutic strategy has been hotly investigated for the treatment of various cancers26,27. In lines with these efforts, we identified an antibiotic drug tigecycline as a dual inhibitor targeting both retinoblastoma and angiogenesis.

The anti-cancer activities of tigecycline has been recently revealed in various cancers, such as leukemia, cervical and breast cancer11,13,15. Of note, tigecycline has been moving forward in clinical trials for the treatment of acute myeloid leukaemia (ClinicalTrial No. NCT01332786) and chronic myeloid leukaemia (ClinicalTrial No. NCT02883036). Our present work adds retinoblastoma to the list of tigecycline-targeted cancers by showing the pro-apoptotic and anti-proliferative activities of tigecycline in multiple retinoblastoma cell lines as well as retinoblastoma xenograft mouse model (Figs 1 and 7). In addition, the preferential selectivity of tigecycline on cancer cells over normal counterparts demonstrates tigecycline as a promising candidate for targeted cancer therapy11,13. We also demonstrated the preferential activity of tigecycline on retinoblastoma cells compared to normal retinal pigment epithelial cells (Supplementary Fig. S1). Tigecycline at doses that effectively inhibit retinoblastoma tumour growth do not cause significant toxicity to mice (Fig. 7). These data agree with the previous work and suggest the therapeutic window of tigecycline on cancer treatment.
We further demonstrated that tigecycline also inhibits angiogenesis through affecting various biological functions of HREC (Fig. 2). We confirmed the inhibitory effects of tigecycline on retinoblastoma angiogenesis in xenograft mouse model (Fig. 8A,B). The inhibition of corneal neovascularization by tigecycline has been shown in a rat model30. Our findings further extend the previous work that tigecycline inhibits angiogenesis induced not only by chemical cauterization but also by tumor progression. Doxycycline, another tetracycline-type antibiotic has also been shown to inhibit choroidal neovascularization31. Our work together with the previous findings suggest the anti-angiogenic activity of tetracycline-type antibiotic. The current clinically used angiogenesis inhibitors, such as sorafenib and bevacizumab, have been shown to only have marginal benefits to cancer patients32. It is possibly because angiogenesis inhibitors target the blood vessels without affecting tumor cells. The ability of tigecycline or tetracycline-type antibiotic in targeting tumor and tumor angiogenesis distinguishes it from anti-cancer compounds that only target cancer cells or angiogenesis inhibitors that only target vascular endothelial cells. Mechanistically, we show that tigecycline acts on retinoblastoma and HERC cells via inhibiting mitochondrial protein translation (Fig. 3A,B). As a consequence of mitochondrial translation inhibition, tigecycline induces mitochondrial dysfunction, energy crisis and oxidative damage (Figs 3–6). Consistent with the results obtained from in vitro cell culture system, we also observed the increased oxidative stress in retinoblastoma tumor exposed to tigecycline (Fig. 8), further confirming mitochondria as the target of tigecycline in retinoblastoma. Apart from mitochondrial translation inhibition, tigecycline has been reported to inhibit Wnt/β-catenin and autophagy in cervical and breast cancer, respectively33. It seems that tigecycline acts on cancer in a cancer type-specific manner, we and others show mitochondrial inhibition as the mechanism of tigecycline's action on most cancers11,13. Substantial recent evidences indicate that many tumours are highly dependent on mitochondrial respiration for growth and survival34–36. In line with these findings, we demonstrate that mitochondrial respiration-deficient retinoblastoma cells have remarkably reduced ATP level and growth (Fig. 6D,E). Our work clearly demonstrate that mitochondrial metabolism plays an important role in retinoblastoma.
Figure 7. Tigecycline significantly inhibits retinoblastoma growth in mice without toxicity. (A) No significant changes on mouse body weight in control and tigecycline-treated groups. (B) Tigecycline significantly inhibits retinoblastoma growth in vivo. *p < 0.05, compared to control. ns, not significant.

Figure 8. Tigecycline significantly inhibits retinoblastoma angiogenesis and induces oxidative stress in vivo. (A) Representative photos of immunohistochemistry of microvascular marker CD31, oxidative stress markers HEL and 4-HNE staining. Tigecycline significantly inhibits retinoblastoma angiogenesis (B) and increases oxidative stress (C,D) in vivo. Intraperitoneal tigecycline at 60 mg/kg once per day were given to the mice. *p < 0.05, compared to control.
In conclusion, we provide evidence that tigecycline is a useful addition to the treatment armamentarium for retinoblastoma by demonstrating tigecycline as a dual inhibitor of retinoblastoma and angiogenesis. The toxicity and efficacy of tigecycline in clinical settings are important and warrant further investigation. Our work also highlights the therapeutic value of targeting mitochondrial metabolism in retinoblastoma.

**Materials and Methods**

**Cell lines, primary cells and mitochondrial respiration-deficient ρ₀ cell line generation.** Human normal retinal pigment epithelial cell line hTERT RPE-1 and human retinoblastoma cell lines Y79, WERI-Rb-1, and RB116 (kind gifts from Dr. Zhi Li) were cultured using RPMI 1640 medium supplemented with 10% FBS, 1% HEPES (Invitrogen, US) and 100 U/mL penicillin-streptomycin (Thermo Fisher Scientific, US). Mitochondrial respiration-deficient ρ₀ cells were generated by culturing Y79 cells in the above medium and selecting using 1 μg/ml ethidium bromide (EtBr), supplemented with 50 μg/ml uridine and 1 mM sodium pyruvate (Sigma, US) for 8 weeks. Human primary retinal microvascular endothelial cells (HREC) (Cell Systems, US) were originated using Serum-Free Medium (SF-4Z0-500, Cell Systems, US), and subsequently grown and passaged in Cell Systems Complete Medium (4Z0-500, Cell Systems, US).

**MTS proliferation.** Cells (5000/well in 96-well plate) were incubated with DMSO or different concentrations of tigecycline (Sigma, US) for 3 days. Proliferation was then determined by using MTS Cell Proliferation Colorimetric Assay Kit (BioVision, US).

** Annexin V labelling and flow cytometry.** Cells (100,000/well in 12-well plate) were treated with DMSO or tigecycline, or Z-V-AD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone, Selleckchem, US). Annexin V labelling and flow cytometry analysis (Beckman Coulter FC500).

**In vitro angiogenesis assay.** The in vitro angiogenesis assay was performed using HREC at passages 2–4 as previously described. Briefly, 2 × 10⁴ HRECs together with DMSO or tigecycline were plated onto the solidified complete Matrigel matrix (BD, Biosciences, US) in 96-well plate. The capillary network was formed after 6–8 h incubation. Photos were taken under light microscopy.

**Boyden chamber migration assay.** HREC (4 × 10⁴/24-well plate) together with DMSO or tigecycline were seeded in the top of the insert in serum-free media and 10% FBS was placed in the lower chamber. After 4–6 h incubation, migratory cells moved through the pores toward the FBS below and were fixed, stained with 0.4% Giemsa (Sigma, US). The cells spreading on the upper surfaces of the filter (non-migrated cells) were wiped away with cotton swabs.

**Immunoblotting.** Cells (2 × 10⁴/6-well plate) together with DMSO or tigecycline were incubated for 24 hours. Samples of cell lysate were prepared for NuPAGE electrophoresis according to the manufacturer’s instructions (Life Technologies, US), followed by electrophoresis and western blot analyses using antibodies against Cox-1, Cox-2, Cox-4 and β-actin (Cell Signalling, US). Immunoband intensities were analysed by Image 4.0 (BioRad).

**Real time-PCR.** Cells (2 × 10⁴/6-well plate) together with DMSO or tigecycline were incubated for 24 hours. Total RNA were extracted from drug-treated cells using TRIzol-based reagent (Invitrogen, US) according to the manufacturer’s instructions. The first-strand cDNA was synthesized with the SuperScript First-strand Synthesis System (Invitrogen, US). Quantitative PCR was carried out using RT2 SYBR Green qPCR MasterMix on CFX96 RT PCR system (Bio-rad, CA). The sequence of primers for human Cox-1, Cox-2, Cox-4, MT-ND6, MT-CO2, and SDHA are the same as previously described. The quantity of the transcript was normalized to the level of β-actin.

**Mito stress test assay.** Cells (20,000/well in 24-well plate) were treated with drug for 24 hours. Oxygen Consumption Rate (OCR, indicative of mitochondrial respiration) was measured at 37°C in a CO₂-free environment on a Seahorse XF24 extracellular flux analyser (Seahorse Bioscience, US) according to Seahorse Bioscience protocols. We measured the basal OCR, and then sequentially injected oligomycin, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone and Antimycin A to assess the maximal OCR.

**Mitochondrial complex activities.** Cells (100,000/well in 12-well plate) were treated with drug for 24 hours. Complex I, II and IV activities were assessed using total cell lysate and were determined using Mitochondrial Complex I, II and IV Activity Assay Kits (Novagen, US) according to manufacturer’s instructions. The activity levels were indicated by the decrease in absorbance in mOD/min at 340 nm (I), 600 nm (II) and 550 nm (IV) in kinetic mode using Tecan Infinite200 Microplate Reader (Mannedorf, Switzerland).

**Cellular ATP and oxidative damage assays.** Cells (100,000/well in 24-well plate) were treated with drug for 24 hours. ATP levels were measured by ATPLite Luminiscent Assay kit (Perkin Elmer, US). DNA was extracted using the DNEasy Mini Kit (Qiagen, US). Oxidative DNA and protein damage was measured by quantifying 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels using the OxiSelect Oxidative DNA Damage ELISA Kit (Cell Bioslabs) and by quantifying protein carbonylation levels using the Protein Carbonyl ELISA Kit (Enzo LifeSciences), respectively. Lipid peroxidation was measured using the Lipid Peroxidation MDA Assay Kit (Abcam) following the manufacturer’s protocol. The absorbance was read on a Spectramax M5 Microplate reader.
Retinoblastoma xenograft in SCID mouse. All animal experiment protocols were approved by the Institutional Animal Care and Use Committee of Wuhan University. Experiments were performed according to the guidelines provide by the Institutional Animal Care and Use Committee of Wuhan University. NOD/SCID mice were obtained from Shanghai Experimental Animal Centre, Chinese Academy of Sciences. 100 μL of Y79 cells suspended in 50%/50% PBS/Matrigel were subcutaneously injected into mice flank. 7 days after injection, once tumours were palpable, mice were treated with vehicle (20%/80% DMSO/saline) or tigecycline (60 mg/kg/d) by intraperitoneal injection (n = 10 per group). Tumour volume (tumour length × width² × 0.5236) was measured two times a week using callipers. 30 days after injection of cells, mice were sacrificed, tumours were excised and frozen in −80°C. Tumour frozen section slides were fixed with 4% paraformaldehyde (Sigma, US), stained with primary antibodies against CD31, HEL and 4-HNE (Cell Signalling, US), and then secondary antibody conjugated with horseradish peroxidase-DAB (3,3’-diaminobenzidine). The nuclei were stained with hematoxylin.

Statistical analyses. The data are expressed as mean and standard deviation. Statistical analyses were performed by unpaired Student’s t test. In multiple comparisons, ANOVA was used for statistical analyses. Values were considered statistically significant at P < 0.05.

Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Kivela, T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. The British journal of ophthalmology 93, 1129–1131, https://doi.org/10.1136/bjo.2008.150292 (2009).
2. Shields, C. A. & Shields, J. A. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Current opinion in ophthalmology 21, 203–212, https://doi.org/10.1097/IOP.0b013e328338676a (2010).
3. Chintagumpala, M., Chevez-Barrios, P., Payssye, E. A., Plon, S. E. & Hurwitiz, R. Retinoblastoma: review of current management. Oncologist 12, 1237–1246, https://doi.org/10.1634/theoncologist.12-10-1237 (2007).
4. Theriault, B. L., Dimaras, H., Galie, B. L. & Corson, T. W. The genomic landscape of retinoblastoma: a review. Clinical & experimental ophthalmology 42, 33–52, https://doi.org/10.1111/ceo.12132 (2014).
5. Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646, https://doi.org/10.1038/323643a0 (1986).
6. Wikenheiser-Brokamp, K. A. Retinoblastoma family proteins: insights gained through genetic manipulation of mice. Cellular and molecular life sciences: CMLS 63, 767–780, https://doi.org/10.1007/s00018-005-5487-5 (2006).
7. Apte, R. S. & Harbour, J. W. Inhibiting angiogenesis in retinoblastoma. Ophthalmic research 39, 188–190, https://doi.org/10.1159/000103578 (2007).
8. Kaewpoowat, Q. & Ostrosky-Zeichner, L. Tigecycline: a critical safety review. Expert Opin Drug Saf 14, 335–342, https://doi.org/10.1517/14740338.2015.97206 (2015).
9. Lamb, R. et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget 6, 4509–4584, https://doi.org/10.18632/oncotarget.3174 (2015).
10. Rose, W. E. & Rybak, M. I. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26, 1099–1110, https://doi.org/10.1592/phco.26.8.1099 (2006).
11. Skrtic, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688, https://doi.org/10.1016/j.ccr.2011.07.015 (2011).
12. Tan, J., Song, M., Zhou, M. & Hu, Y. Anti-tigecycline enhances cisplatin activity against human hepatocellular carcinoma through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun 483, 17–23, https://doi.org/10.1016/j.bbrc.2017.01.021 (2017).
13. Wang, B. et al. Inhibition of mitochondrial translation effectively sensitizes renal cell carcinoma to chemotherapy. Biochem Biophys Res Commun 490, 767–773, https://doi.org/10.1016/j.bbrc.2017.06.115 (2017).
14. Li, H. et al. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/beta-catenin signaling. Biochem Bioophys Res Commun 467, 14–20, https://doi.org/10.1016/j.bbrc.2015.09.140 (2015).
15. Tang, C. L. et al. Antibiotic drug tigecycline inhibited cell proliferation and induced autophagy in gastric cancer cells. Biochem Biophys Res Co 446, 105–112, https://doi.org/10.1016/j.bbrc.2014.02.043 (2014).
16. Marbach, E. F. et al. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. The British journal of ophthalmology 87, 1224–1228 (2003).
17. Hu, H. et al. Characterization and retin cell differentiation of WERI-Rb1 cancer stem cells. Molecular vision 18, 2388–2397 (2012).
18. Beijani, A. et al. RB116: an RB1+ retinoblastoma cell line expressing primitive markers. Molecular vision 18, 2805–2813 (2012).
19. Madreperla, S. A., Bookstein, R., Jones, O. W. & Lee, W. H. Retinoblastoma cell lines Y79, RB55 and WERI-Rb27 are genetically related. Ophthalmic paediatrics and genetics 12, 49–56 (1991).
20. Fu, X. et al. Targeting mitochondrial respiration selectively sensitizes pediatric acute lymphoblastic leukemia cell lines and patient samples to standard chemotherapy. Am j Cancer Res 7, 2395–2405 (2017).
21. Tam, E. W. et al. A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis. Neuropediatrics 39, 328–334, https://doi.org/10.1055/s-0039-1602287 (2008).
22. Ott, N. & Herrmann, J. M. Co-translational membrane insertion of mitochondrial encoded proteins. Biochim Biophys Acta 1803, 767–775, https://doi.org/10.1016/j.bbamcr.2009.11.010 (2010).
23. Chandel, N. S. & Schumacker, P. T. Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. FEBS Lett 454, 173–176, doi:10.1111/j.0014-5793.9900783-8 [pii] (1999).
24. Burnier, M. N., McLean, I. W., Zimmerman, L. E. & Rosenberg, S. H. Retinoblastoma. The relationship of proliferating cells to blood vessels. Invest Ophthalmal Vis Sci 31, 2037–2040 (1990).
25. Garcia, J. R. et al. Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2. Arch Pathol Lab Med 139, 1531–1538, https://doi.org/10.5858/arpa.2014-0262-OA (2015).
26. Yang, H. et al. PDEF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 100, 2419–2425, https://doi.org/10.1111/csc.12901 (2019).
27. Lee, S. Y., Kim, D. K., Cho, J. H., Koh, J. Y. & Yoon, Y. H. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Archives of ophthalmology 126, 953–958, https://doi.org/10.1001/archophth.126.7.953 (2008).
28. Moser, C. et al. Targeting HSPP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 32, 2551–2561 (2012).
29. Li, Z. et al. Inhibition of Wnt/beta-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma. *American journal of translational research* **9**, 3776–3786 (2017).
30. Goktas, S. et al. Inhibition of corneal neovascularization by topical and subconjunctival tigecycline. *Journal of ophthalmology* **2014**, 452685, https://doi.org/10.1155/2014/452685 (2014).
31. Samtani, S., Amaral, J., Campos, M. M., Faris, R. N. & Becerra, S. P. Doxycycline-mediated inhibition of choroidal neovascularization. *Invest Ophthalmol Vis Sci* **50**, 5096–5106, https://doi.org/10.1167/iovs.08-3174 (2009).
32. Cook, K. M. & Figg, W. D. Angiogenesis inhibitors: current strategies and future prospects. *CA Cancer J Clin* **60**, 222–243, https://doi.org/10.3322/caac.20075 (2010).
33. Lu, Z. et al. Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia. *Journal of experimental & clinical cancer research: CR* **36**, 43, https://doi.org/10.1186/s13046-017-0512-6 (2017).
34. Johnson, J. M. et al. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. *Semin Oncol* **42**, 915–922, https://doi.org/10.1053/j.seminoncol.2015.09.025 (2015).
35. Zhang, X. et al. Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. *International journal of molecular sciences* **16**, 27313–27326, https://doi.org/10.3390/ijms161126020 (2015).
36. Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. *Nat Chem Biol* **11**, 9–15, https://doi.org/10.1038/nchembio.1712 (2015).
37. Hashiguchi, K. & Zhang-Akiyama, Q. M. Establishment of human cell lines lacking mitochondrial DNA. *Methods Mol Biol* **554**, 383–391, https://doi.org/10.1007/978-1-59745-521-3_23 (2009).
38. Harada, Y., Ishii, I., Hatake, K. & Kasahara, T. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. *Cancer Lett* **319**, 83–88, https://doi.org/10.1016/j.canlet.2011.12.034.

Acknowledgements
This work was supported by research grants provided by Hubei Province Development Planning & Research Institute (220100455) and Nature Science Foundation of Hubei Province (2011CDB526).

Author Contributions
Y.X., W.L, X.D.F. designed experiments. Y.X. W.L., Q.H., J.W. and Y.J.W. performed experiments. H.J.L. performed bioinformatics analysis. X.D.F. wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29938-x.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018